IDEXX Laboratories, Inc. (FRA:IX1)
Germany · Delayed Price · Currency is EUR | Market Cap | 37.58B -14.4% |
| Revenue (ttm) | 3.99B +12.8% |
| Net Income | 997.54M +15.6% |
| EPS | 12.45 +18.4% |
| Shares Out | n/a |
| PE Ratio | 37.68 |
| Forward PE | 35.42 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 474.60 |
| Previous Close | 465.10 |
| Day's Range | 474.60 - 474.60 |
| 52-Week Range | 450.10 - 665.80 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About IDEXX Laboratories
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides com... [Read more]
Financial Performance
In 2025, IDEXX Laboratories's revenue was $4.30 billion, an increase of 10.42% compared to the previous year's $3.90 billion. Earnings were $1.06 billion, an increase of 19.33%.
Financial numbers in USD Financial StatementsNews
IDEXX Laboratories Transcript: Investor Day 2026
Innovation in diagnostics, software, and AI is driving sector growth, with new products like inVue Dx and Cancer Dx expanding care and recurring revenue. Strong commercial execution and global expansion support high customer loyalty and double-digit growth, while financial discipline underpins robust margins and free cash flow.
IDEXX Laboratories Slides: FY 2026
IDEXX Laboratories has posted slides in relation to its FY 2026 quarterly earnings report, which was published on August 13, 2026.
IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX announces Catalyst™ proBNP Test, the first and only dual-species, in-clinic diagnostic assay for cardiac assessment.
IDEXX Laboratories Earnings Call Transcript: Q2 2026
Q2 2026 delivered 10% revenue growth and 18% EPS growth, driven by strong CAG Diagnostics, international expansion, and innovation adoption. Full-year guidance was raised for revenue, EPS, and free cash flow conversion, with continued investments in R&D and commercial capabilities.
IDEXX Laboratories Earnings release: Q2 2026
IDEXX Laboratories released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
IDEXX Laboratories Slides: Q2 2026
IDEXX Laboratories has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
IDEXX Laboratories Quarterly report: Q2 2026
IDEXX Laboratories has published its Q2 2026 quarterly earnings report on August 4, 2026.
IDEXX Laboratories Announces Second Quarter Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced second quarter results. Second Quarter Results The Company rep...
IDEXX Releases 2025 Corporate Responsibility Report, Highlighting Progress Against Its Goals
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX releases 2025 Corporate Responsibility Report highlighting progress against its goals and commitments.
IDEXX Laboratories to Release 2026 Second Quarter Financial Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 second quarter financial results for Tue...
IDEXX Laboratories Transcript: Stifel Jaws & Paws Conference 2026
The new CEO is driving a purpose-led strategy focused on innovation, global expansion, and integrated diagnostics and software. AI and new platforms like inVue Dx and Cancer Dx are fueling growth, with strong adoption and expanding capabilities. The company expects continued momentum from a robust pipeline and sector tailwinds.
IDEXX Expands Fecal Dx Antigen Testing Platform with Taeniid Tapeworm Detection
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX expands Fecal Dx™ antigen testing with taeniid tapeworm detection for broader intestinal parasite screening in wellness and sick-pet care.
IDEXX SDMA Now Integrated into the Most Common Catalyst Chemistry Profiles
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX integrates SDMA into most common Catalyst chemistry profiles, enabling earlier detection of kidney disease through routine in‑clinic testing.
IDEXX Laboratories to Present at Stifel Conference and Announces 2026 Investor Day
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, wil...
IDEXX Laboratories Transcript: AGM 2026
The meeting featured a CEO transition, approval of all management proposals including board declassification and special meeting rights for 25% shareholders, and rejection of a shareholder proposal for a 10% threshold. No questions were raised during the Q&A.
IDEXX Laboratories Earnings Call Transcript: Q1 2026
Q1 2026 saw 14% reported and 11% organic revenue growth, with strong gains in CAG Diagnostics, premium instrument placements, and international markets. Full-year guidance was raised for revenue, EPS, and operating margin, supported by innovation and robust customer retention.
IDEXX Laboratories Earnings release: Q1 2026
IDEXX Laboratories released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
IDEXX Laboratories Slides: Q1 2026
IDEXX Laboratories has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
IDEXX Laboratories Quarterly report: Q1 2026
IDEXX Laboratories has published its Q1 2026 quarterly earnings report on May 5, 2026.
IDEXX Laboratories Announces First Quarter Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results. First Quarter Results The Company repor...
University of New England launches new Institute of Public and Planetary Health in honor of philanthropist and IDEXX Founder David Evans Shaw
A $5 million gift from the storied entrepreneur, activist, and impact investor will advance the University of New England's work at the intersection of environmental and human health while boosting Ma...
IDEXX Laboratories to Release 2026 First Quarter Financial Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 first quarter financial results for Tues...
IDEXX Announces UK Availability of Cancer Dx Panel for Early Detection of Canine Lymphoma
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Cancer Dx Panel with canine lymphoma detection helps clinicians investigate sooner and plan next steps with confidence.
IDEXX Laboratories Proxy statement: Proxy filing
IDEXX Laboratories filed a proxy statement on March 27, 2026, providing details for shareholder voting and corporate governance matters.
IDEXX Laboratories Proxy statement: Proxy filing
IDEXX Laboratories filed a proxy statement on March 27, 2026, providing details for shareholder voting and corporate governance matters.